Two years ago, Acorda Therapeutics Inc. CEO Ron Cohen was sitting in the witness chair in the US District Court for the District of Delaware, trying to convince US District Judge Leonard Stark that the company's lead product Ampyra (dalfampridine) was a novel invention worthy of its patent protection.
Flash forward to today and the company has been through quite a re-invention. Acorda lost the patent infringement case and...






